Statement: the primary clinical trial's first and second cohorts mostly recorded instances of disease relapse, contralateral breast cancer, second primary cancer, or death for reasons that are unrelated to the aforementioned medical conditions
Primary_evidence: Outcome Measurement:    Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer   The percentage of patients alive and cancer-free.   Time frame: 5 years Results 1:    Arm/Group Title: Group 1: TAC X 6   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel.   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed: 1610   Measure Type: Number   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) Results 2:    Arm/Group Title: Group 2: AC X 4 Then P X 4   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed: 1618   Measure Type: Number   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)